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Abstract
Background: Autophagy is a highly conserved and regulated cellular process employed by living cells to degrade proteins
and organelles as a response to metabolic stress. We have previously reported that eukaryotic elongation factor-2 kinase
(eEF-2 kinase, also known as Ca
2+/calmodulin-dependent protein kinase III) can positively modulate autophagy and
negatively regulate protein synthesis. The purpose of the current study was to determine the role of the eEF-2 kinase-
regulated autophagy in the response of breast cancer cells to inhibitors of growth factor signaling.
Methodology/Principal Findings: We found that nutrient depletion or growth factor inhibitors activated autophagy in
human breast cancer cells, and the increased activity of autophagy was associated with a decrease in cellular ATP and an
increase in activities of AMP kinase and eEF-2 kinase. Silencing of eEF-2 kinase relieved the inhibition of protein synthesis,
led to a greater reduction of cellular ATP, and blunted autophagic response. We further showed that suppression of eEF-2
kinase-regulated autophagy impeded cell growth in serum/nutrient-deprived cultures and handicapped cell survival, and
enhanced the efficacy of the growth factor inhibitors such as trastuzumab, gefitinib, and lapatinib.
Conclusion/Significance: The results of this study provide new evidence that activation of eEF-2 kinase-mediated
autophagy plays a protective role for cancer cells under metabolic stress conditions, and that targeting autophagic survival
may represent a novel approach to enhancing the effectiveness of growth factor inhibitors.
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Introduction
Autophagy is a highly conserved process by which cytoplasm and
organelles are digested via autophagosomes and autolysosomes and
cellularcomponentsarerecycled forenergyutilization[1,2].During
starvation or growth factor deficiency, autophagy may serve as a
temporary survival mechanism by providing an alternative energy
source. Autophagy can also optimize nutrient utilization in rapidly
growing cells when faced with hypoxic or metabolic stresses, thus
contributing to cancer cell survival [3,4,5]. eEF-2 kinase, a Ca
2+/
calmodulin-dependent protein kinase, acts as a negative regulator of
protein synthesis: this kinase phosphorylates eEF-2, a 100 kDa
protein that mediates the translocation step in peptide-chain
elongation by inducing the transfer of peptidyl-tRNA from the
ribosomal A to P site; phosphorylation of eEF-2 at Thr56 by eEF-2
kinase decreases the affinity of the elongation factor for ribosome
and terminates elongation [6]. Our previous studies demonstrated
that eEF-2 kinase might be a central component of the mammalian
macroautophagy pathway that is activated in response to nutrient
deprivation [7,8]. The role of eEF-2 kinase in the regulation of
stress-induced autophagy has further been confirmed by others [9].
Since protein synthesis is a major energy-consuming process,
termination of protein synthesis and induction of autophagy via
activation of eEF-2 kinase should conserve energy and support cell
survival duringtime of metabolic stress.Moreover, eEF-2kinasehas
beenfound to be overexpressed and its activity increased in multiple
breast cancer cell lines and human breast cancer specimens as
compared to adjacent normal tissue [10].
The members of the epidermal growth factor receptor (EGFR)
family such as EGFR/HER1 and HER2/erB2 represent attractive
targets for therapeutic intervention in treatment of cancer, due to
the roles of these receptor tyrosine kinases in stimulating oncogenic
signaling pathways and in the development and progression of
cancers [11,12,13]. Aberrant expression or activity of the EGFR
family receptor tyrosine kinases is encountered in many types of
malignancies including breast cancers. Indeed, the EGFR tyrosine
kinase inhibitors such as lapatinib and gefitinib, and the HER2/
neu-targeted agent trastuzumab, have been shown to possess
notable antitumor activity in several types of cancers [14]. These
drugs can specifically bind to the receptors with high affinity,
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inhibition of tumor growth. Nevertheless, refractoriness to these
growthfactorinhibitorsiscommon[15,16].Forinstance,inpatients
with HER2-positive metastatic breast cancers, the response rate of
trastuzumab is only ,26% [17]. Thus, understanding of the
mechanisms underlying the insensitivity to the growth factors
inhibitors and developing approaches to sensitizing tumor cells will
make these drugs more valuable in treating patients with cancer. In
this study, we sought to determine whether activation of eEF-2
kinase-mediated autophagy altered sensitivity of human breast
cancer cells to inhibition of growth factor-initiated signaling, and
whether modulating autophagy via targeting eEF-2 kinase would
render tumor cells more susceptible to the effect of growth factor
inhibitors. Our study shows that the eEF-2 kinase-mediated
autophagy plays a cytoprotective role in breast cancer cells treated
withgrowthfactorinhibitors,and inhibitingautophagicsurvivalcan
modulate sensitivity to these therapeutic agents.
Results
Nutrient deprivation and growth factor inhibitors
activated autophagy in human breast cancer cells
To determine the effect of metabolic stress on autophagy, we
first treated the human breast cancer cells MCF-7 with DPBS, and
then examined autophagic activity in the treated cells. As shown in
Fig. 1A, nutrient deprivation increased the level of LC3-II, a
specific marker of autophagic activity. Autophagosome formation
was confirmed by GFP-LC3 puncta localization (Fig. 1B). We
further found that MCF-7 and MDA-MB-468 breast cancer cells
treated with the growth factor inhibitors, gefitinib and lapatinib,
showed an increased in LC3-II amount in a dose-dependent
manner, as determined by Western blot (Fig. 1C and D). The
effects of gefitinib and lapatinib on autophagy were verified using
GFP-LC3 cleavage assay (Fig. 1E). These observations suggest
that activation of autophagy may represent a cellular response
to metabolic stress, including treatment with growth factor
inhibitors.
Nutrient deprivation caused a reduction of protein
synthesis and cellular ATP
To ascertain whether a causal relationship exists between
activation of autophagy and metabolic stress in breast cancer cells,
we measured protein synthesis activity and ATP level in MCF-7
cells subjected to nutrient starvation. As shown in Fig. 2, treatment
of the cells with DPBS (Dulbecco’s Phosphate-Buffered Saline)
caused a marked decrease in protein synthesis (Fig. 2A) and ATP
content (Fig. 2B). Cellular response to energy stress was also
evidenced by an increased phosphorylation on Thr172 of AMP-
activated protein kinase (AMPK), an intracellular energy sensor
that is activated when cellular energy level decreases (Fig. 2C).
Figure 1. Effect of nutrient deprivation and growth factor inhibitors on autophagy in human breast cancer cells. (A) MCF-7 cells were
treated with DPBS for the indicated times. At the end of treatment, formation of the autophagy marker LC3-II was detected by immunoblotting with
an anti-MAP-LC3 antibody. (B) MCF-7 cells transfected with 3 mg of GFP-LC3 plasmid were treated or untreated with DPBS for 1 h, and then observed
under a fluorescent microscope. A representation of GFP-LC3 positive cells was shown. (C, D) MCF-7 (C) or MDA-MB-468 (D) cells cultured in medium
containing 10% FBS were treated with 0.5, 1, 2.5, 5 or 10 mM gefitinib or lapatinib for 24 h, and the LC3-II level was examined by immunoblotting. (E)
MDA-MB-468 cells were transfected with a GFP-LC3-expressing vector, and then treated with the indicated concentration of gefitinib or lapatinib in
the presence of the lysosomal protease inhibitors E64d (10 mg/ml) and pepstain A (10 mg/ml). At the end of treatments, cells were fixed with 4%
formaldehyde for 15 min. To determine the autophagic response, cells were inspected at 606magnification for numbers of GFP-LC3 puncta.
doi:10.1371/journal.pone.0009715.g001
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mTOR/S6 kinase pathway
We next determined the effects of nutrient deprivation on the
activity of eEF-2 kinase, a unique calmodulin-dependent enzyme
that inhibits protein synthesis and activates autophagy, and on the
signaling molecules associated with the regulation of the activity of
this kinase. Fig. 3A shows that treatment of MCF-7 cells with DPBS
activated eEF-2 kinase, as measured by the phosphorylation of EF-
2, the substrate for the kinase. Activation of eEF-2 kinase was also
manifested in an increased auto-phosphorylation on Ser398, which
is known to positively regulate the activity of this kinase, and in a
decreased phosphorylation of the kinase on Ser366, a site known to
negatively regulate the activity of this enzyme (Fig. 3A). The activity
of S6 kinase, a key translation controller downstream of mTOR,
was decreased, as evidenced by a decrease in the phosphorylation
on Thr389 of S6 kinase (Fig. 3B). The activity of 4EBP1, a
translation repressor, was increased, as shown by a decrease in the
phosphorylation of this protein (Fig. 3B).
eEF-2 kinase was involved in autophagy induction and
ATP reduction in response to nutrient depletion
To analyze whether eEF-2 kinase plays a regulatory role in
nutrient starvation-induced reduction of protein synthesis and
ATP content and in activation of autophagy in breast cancer cells
stressed with nutrient depletion, we silenced EF-2 kinase
expression using siRNA, and then measured ATP level, protein
synthesis and autophagy activity following treatment with DPBS.
As shown in Fig. 4A, inhibition of eEF-2 kinase by siRNA
decreased starvation-induced autophagy. Inhibition of eEF-2
kinase also resulted in mitigation of the nutrient depletion-induced
inhibition of protein synthesis (Fig. 4B) and led to further reduction
of ATP levels (Fig. 4C). These results further support a role for
eEF-2 kinase in activating autophagy in metabolically stressed
tumor cells.
Suppression of autophagy decreased growth and
survival of metabolically stressed breast cancer cells
To further test our hypothesis that autophagy plays a pro-
survival role in response to a compromised supply of cellular
nutrients and growth factors during breast cancer development
and progression, we knocked down eEF-2 kinase, beclin-1 or
ATG5 (two of the key autophagy-related genes) in MCF-7 cells
(Fig. 5A), and then compared the growth and survival of these
autophagy-deficient cells with that of the cells transfected with a
non-targeting RNA in serum-free medium or HBSS. As shown in
Fig. 5B, suppression of autophagy by knockdown of those
autophagy-regulated genes hindered the tumor cell growth in
the absence of serum. Knockdown of eEF-2 kinase, beclin-1 or
ATG5 also caused more death of MCF-7 cells cultured in HBSS
(Fig. 5C). The autophagy inhibitor, 3-MA, was used as a control
and showed a similar inhibitory effect on cell growth and survival
in the absence of serum or nutrients (Fig. 5B and C).
Figure 2. Effect of nutrient deprivation on protein synthesis and cellular ATP in MCF-7 cells. (A) MCF-7 cells were treated with DPBS for
the indicated times and the rate of protein synthesis was measured by labeling the cells with 25 mCi/ml of EasyTag EXPRESS [
35S] protein labeling mix
and liquid scintillation counting, as described in ‘‘Material and Methods’’. The specific activity of protein synthesis was determined by the amounto f
incorporated
35S-methionine/cysteine per mg of total protein per min, and relative activities at indicated times of starvation were calculated as
percent of control. Results shown are the mean 6 SD of quadruplicate determinations from one of three identical experiments; *p,0.05, t-test. (B)
MCF-7 cells were treated with DPBS for the indicated times and ATP content was measured using the ATPlite
TM Luminescence Assay Kit. (C) AMPK
activity was determined by Western blot analysis of phospho-AMPK using an anti-phospho-AMPK antibody, as described in ‘‘Material and Methods’’.
Actin was used as a loading control. Results shown are the representative of three similar experiments; each bar or point represents mean 6 SD of
quadruplicate determinations. Results shown are the mean 6 SD of quadruplicate determinations from one of three identical experiments; **p,0.01,
t-test.
doi:10.1371/journal.pone.0009715.g002
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ATP. (A) MCF-7 cells were transfected with a non-targeting RNA or an eEF-2 kinase-targeted siRNA (100 nM) for 72 h, and then treated with DPBS for
1 h. eEF-2 kinase, phosphor-EF-2, and the autophagy marker, LC3-II, were detected by Western blot. (B) MCF-7 cells with or without silencing of eEF-2
kinase were treated with DPBS; at the indicated times, cells were harvested for protein synthesis assay. Results shown are the mean 6 SD of
quadruplicate determinations from one of three identical experiments; *p,0.05, t-test. (C) MCF-7 cells transfected with 50 nM of NT RNA or an eEF-2
kinase siRNA were seeded in 96-well tissue culture plates (1610
4 cells per well). Forty-eight h later, the cells were starved in DPBS for 1 h, 2 h and 4 h.
Cells were collected at the end of starvation for ATP assay. Results shown are the mean 6 SD of quadruplicate determinations from one of three
identical experiments; *p,0.05, **p,0.01, t-test.
doi:10.1371/journal.pone.0009715.g004
Figure 3. Effect of nutrient deprivation on eEF-2 kinase activity and the associated signaling molecules. (A) MCF-7 cells were treated
with DPBS for the indicated times, and the levels of eEF-2 kinase, p-EF2, EF2, p-eEF2 kinase (S398) and p-eEF2 kinase (S366) were examined by
Western blot using the respective antibodies. (B) MCF-7 cells were treated with DPBS for the indicated times, and p-S6 kinase, S6 kinase, p-4EBP1, and
4EBP1 were examined by Western blot using the respective antibodies. b-actin was used as a loading control. Results shown are the representative of
three similar experiments.
doi:10.1371/journal.pone.0009715.g003
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growth factor inhibitors
To determine whether suppression of the eEF-2 kinase-
mediated autophagy alters sensitivity of tumor cells to growth
factor inhibitors that are in clinical use, we first transfected MCF-7
cells with an eEF-2 kinase-targeted siRNA or a non-targeting
RNA, and then treated the transfected cells with a series of
concentrations of gefitinib or lapatinib. Fig. 6A and B show that
silencing of EF-2 kinase expression increased sensitivity of MCF-7
cells to gefitinib and lapatinib. Similar results were observed with
the human breast cancer cells MDA-MB-468 (Fig. 6C and D).
Inhibition of autophagy by an eEF-2 kinase-targeted siRNA also
enhanced the cytotoxic effects of a small molecule EGFR/ErbB-2
inhibitor (EEi) and trastuzumab, an anti-Her2 therapeutic
antibody (Table 1). Combined use of the inhibitors of growth
factor and autophagy produced combination indexes (CIs) smaller
than 1 (Table 1), indicating a synergism between the actions of
those treatments.
Discussion
A number of molecular mechanisms have been revealed to
contribute to resistance of cancer to drugs that target growth factor
receptor-initiated signaling pathways. These known mechanisms
include overexpression or mutation of EGFR [18], co-activation of
multiple receptor tyrosine kinases [19,20], mutation or alteration
in the downstream effectors of EGFR such as loss of PTEN [21],
and compensatory pathways that remain active in stimulating PI-3
kinase [22]. Here, we identified the activation of the eEF-2 kinase-
mediated autophagy as a new mechanism responsible for the
insensitivity of cancer cells to growth factor inhibition. We found
that breast cancer cells utilize autophagy to survive nutrient
deficiency and growth factor inhibitors, and eEF-2 kinase also
plays an important role in the induction of autophagy triggered by
growth factor inhibitors. We demonstrate that inhibitors of growth
factors such as gefitinib and lapatinib can induce autophagy in
breast cancer cells (Fig. 1), and the nutrient depletion-induced
autophagy is associated with activation of eEF-2 kinase via the
Figure 5. Effects of autophagy suppression on growth and survival of human breast cancer cells. (A) MCF-7 cells were transfected with a
non-targeting RNA or a siRNA targeting eEF-2 kinase, beclin1, or ATG5. Expressions of eEF-2 kinase, beclin1, or ATG5 were determined by Western
blot using the respective antibodies. b-actin or Ran was used as a loading control. (B) MCF-7 cells treated with 3-MA or with siRNA targeting eEF-2
kinase, beclin1, ATG5 or a non-targeting RNA were seeded with 10% FBS RPMI 1640 medium in 96-well culture plates (3610
3 cells per well). After
overnight incubation, medium was changed to serum-free medium. Cell viability was determined at the indicated times using MTT assay. Results
shown are the representative of three similar experiments; each point represents mean 6 SD of quadruplicate determinations. (C) MCF-7 cells treated
with 3-MA or with siRNA targeting eEF-2 kinase, beclin1, ATG5 or a non-targeting RNA were seeded with 10% FBS RPMI 1640 medium in 96-well
culture plates (3610
3 cells per well). After overnight incubation, medium was changed to HBSS. Cell viability was determined at the indicated times
using MTT assay. Results shown are the representative of three similar experiments; each point represents mean 6 SD of quadruplicate
determinations.
doi:10.1371/journal.pone.0009715.g005
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show that inhibiting the eEF-2 kinase-mediated autophagy can
sensitize breast cancer cells to growth factor inhibitors (Fig. 6,
Table 1). The results of the current study are consistent with our
previous findings that eEF-2 kinase plays a critical role in
autophagic survival of stressed tumor cells [7,8]. A recent report
by Vazquez-Martin et al. shows that autophagy also plays an
essential role in the development of resistance to trastuzumab, an
anti-Her2 therapeutic antibody, in breast cancer exposed
chronically to this agent [23].
A variety of anticancer therapies induce autophagy, including
antiestrogens [24], radiation [25], inhibitors of histone deacety-
lases [26] and chemotherapy [27,28]. Whether the autophagic
response is a pathway to cell death or a mechanism of survival (or
both) remains uncertain. For instance, vinblastine increased the
number of autophagosomes in pre-neoplastic pancreatic acini
[29], whereas pancreatic cancer cells had a decreased autophagic
response to vinblastine [30]. Radiation increased autophagy in
glioma cell lines, but whether this was a survival or death response
remains unclear, since the autophagic changes were independent
of sensitivity to radiation [31]. More recently, it was reported that
blocking autophagy could enhance the sensitivity of breast cancer
to radiation [25]. It is likely that the pro-survival or pro-death role
of autophagy is context-dependent.
Several points during breast cancer progression are character-
ized by a compromised supply of cellular nutrients and growth
factors. For instance, when transformed cells invade the stroma or
land in a metastatic site, these cells are temporarily ‘‘cut off’’ from
a robust blood supply, decreasing access to oxygen, estrogen,
glucose, amino acids, and other growth factors. To survive this
nutrient-depleted state, breast cancer cells (much like neonates)
could utilize autophagy to generate ATP from recycled organelles
Figure 6. Effects of eEF-2 kinase silencing on sensitivity of human breast cancer cells to growth factor inhibitors. MCF-7 (A, B) and
MDA-MB-468 (C, D) cells transfected with an siRNA targeting eEF-2 kinase or a non-targeting RNA were cultured in RPMI 1640 or DMEM media
supplemented with 10% fetal bovine serum at 37uC in a humidified incubator (5% CO2 and 95% air), and then treated with a series of concentrations
of gefitinib (A, C) or lapatinib (B, D) for 48 h. At the end of treatment, cell viability was determined using MTT assay. Results shown are the
representative of three similar experiments; each point represents mean 6 SD of quadruplicate determinations; *p,0.05, **p,0.01, t-test.
doi:10.1371/journal.pone.0009715.g006
Table 1. CompuSyn analysis of the combinations of growth
factor inhibitors and eEF-2 kinase siRNA.
Cell types Samples CI values
MCF7 Gefitinib: eEF-2K siRNA 0.45
Lapatinib: eEF-2K siRNA 0.42
EEi: eEF-2K siRNA 0.51
Trastuzumab: eEF-2K siRNA 0.60
MDA-MB-468 Gefitinib: eEF-2K siRNA 0.40
Lapatinib: eEF-2K siRNA 0.53
EEi: eEF-2K siRNA 0.65
Trastuzumab: eEF-2K siRNA 0.67
Combination index (CI) was calculated using the computer program,
CompuSyn.
doi:10.1371/journal.pone.0009715.t001
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limit protein synthesis to prevent the critical depletion of ATP.
This is accomplished through inhibition of eIF4 and activation of
eEF2-kinase to inhibit protein synthesis. Indeed, our studies
demonstrated that failure to activate eEF-2 kinase blocked
autophagy (Fig. 4), handicapped cell growth (Fig. 5B) and hastened
cell death (Fig. 5C). Additionally, as recently shown by us [7] and
others [32,33], the activity of mTOR and S6 kinase are decreased
following nutrient/growth factor deprivation and this relieves the
inhibition of eEF-2 kinase [34]. Since protein synthesis devours
ATP, termination of protein elongation via activation of eEF-2
kinase should conserve energy and support cell survival during
times of starvation. Furthermore, cells depleted of eEF-2 kinase
were unable to tolerate nutrient withdrawal as manifested by
accelerated loss of viability when grown in serum-free media
(Fig. 5), likely due to a critical depletion of ATP because of
continued protein synthesis in the face of inadequate nutrients.
This may also explain the increased sensitivity to growth factor
inhibitors in tumor cells with silencing of eEF-2 kinase (Fig. 6,
Table 1). MCF-7 cells are known to be deficient in caspase-3 and
haplo-insufficient in beclin 1 [35,36]; however, in our study we
found that the responses of MCF-7 cells to nutrient deprivation or
growth factor inhibitors are not different from other breast cancer
cell lines such as MDA-MB-468, suggesting that the effects of
inhibiting eEF-2 kinase on autophagic response and cell survival/
death are independent of caspase-3 and beclin 1.
In summary, the results reported here provide new evidence that
activation of eEF-2 kinase and autophagy plays a protective role for
breast cancer cells under metabolic stress including growth factor
inhibition. By inhibiting autophagy, breast cancer cells should be
less able to cope with nutrient/growth factor deprivation, resulting
in better therapeutic outcomes for breast cancer patients. Thus,
targeting the eEF-2 kinase-regulated autophagic survival may be
exploited as a novel approach to preventing and overcoming
refractoriness of cancer cells to growth factor inhibitors.
Materials and Methods
Reagents, antibodies and cell lines
Dulbecco’s phosphate buffered saline (DPBS) and Hank’s
balanced salt solution (HBSS) were purchased from Invitrogen
(Carlsbad, CA). E64, pepstatin A, protease inhibitor cocktail,
phenylmethylsulfonyl fluoride (PMSF), 3-methyladenine (3-MA),
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), dimethyl sulfoxide (DMSO), trichloroacetic acid, anti-b-
actin and anti-ran antibodies were purchased from Sigma-Aldrich
(Saint Louis, MO). Anti-eEF-2 kinase, anti-phospho-eEF-2 kinase
(S366), anti-eEF-2, and anti-phospho-eEF-2 (T56) antibodies were
purchased from Cell Signaling Technologies (Beveley, MA). Anti-
LC3B antibody was purchased from Novus Biologicals (Littleton,
CO) and anti-BECN1 and anti-ATG5 antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-eEF-2 kinase
(S398) antibody was a gift from Dr. Chistopher Proud (University
of Dundee, UK). Human Breast cancer cell lines MCF-7 and
MDA-MB-468 were obtained from American Type Culture
Collection (ATCC, Manassa, VA). Cells were maintained in
RPMI 1640 or DMEM medium supplemented with 10% fetal
bovine serum at 37uC in a humidified incubator (5% CO2 and
95% air).
siRNA and plasmid DNA transfection
For siRNA transfection, ON-TARGET plus siRNA oligos
(Dharmacon, Lafayette, CO) and Oligofectamine (Invitrogen)
were diluted with OPTI-MEM I reduced serum medium first, and
then incubated for 20 minutes before adding to cell culture. Cells
were transfected with siRNA for 24,72 hours. The eEF-2 kinase
siRNA (AAGCUCGAACCAGAAUGUCAA) was customer-de-
signed and synthesized by Dharmacon. siRNA targeting human
BECN1 (J-0105552-05) or human ATG5 (J-004374-07) and the
non-targeting control siRNA (siCONTROL, D-001810-01) were
purchased from Dharmacon. For plasmid DNA transfection, cells
were tansfected with the mixture of plasmid pEGFP-LC3 and
Lipofectamine 2000 (Invitrogen) in OPTI-MEM I reduced serum
medium. After 6-hour incubation at 37uC, transfection medium
was replaced with RPMI 1640 medium without antibiotics. GFP
expression was detected under an inverted fluorescent microscope.
Transfectants were selected with 600 mg/mL of G418 (Invitrogen)
and maintained with 300 mg/ml of G418.
Western blot analysis
Cells were washed twice with ice-cold PBS and scraped off the
tissue culture dishes. Cells were collected in microcentrifuge tubes
and centrifuged at 10006g for 5 minutes. Cell pellets were lysed in
ice-cold lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM ß-glycerolphosphate, 1 mM Na3VO4,1 x
protease inhibitor cocktail, and 1 mM PMSF] and sonicated for 5
seconds. The lysates were clarified by centrifugation at 13,0006g
for 15 minutes at 4uC. Thirty mg of proteins were resolved by SDS-
PAGE and transferred to ImmunoBlot PVDF membrane (Bio-
Rad Laboratories, Hercules, CA), and the membranes were
probed with the respective antibodies. Pierce ECL Western
Blotting Substrate kit (Pierce, Rockford, IL) was used to detect
protein signals on the immuno-blots.
Assay of protein synthesis
Protein synthesis rate was measured with a radio-labeling assay
[37]. Briefly, cells seeded in 60-mm culture dishes were labeled
with 25 mCi per ml of EasyTag EXPRESS
35S protein labeling
mix (PerkinElmer, Boston, MA) in RPMI 1640 medium. After
incubation at 37uC for 15 min, cells were washed 4 times with
4 ml of ice-cold PBS and then lysed in 200 ml of Complete Lysis-
M lysis reagent with 1 Mini Protease Inhibitor Cocktail tablet per
10 ml of lysis reagent (Roche Diagnostics, Indianapolis, IN). Cell
lysates were collected in a microfuge tube and clarified by
centrifugation at 130006g for 10 min at 4uC. Supernatant was
precipitated with 20% of trichloroacetic acid and collected on GF/
C filters (Millipore, Bedford, MA). Filters were washed 4 times
with 1 ml of 10% trichloroacetic acid and subject to liquid
scintillation counting. The specific activity of protein synthesis was
determined by the amount of incorporated
35S-methionine/
cysteine per mg of total protein per min.
GFP-LC3 cleavage
Cells were transfected with a GFP-LC3-expressing plasmid.
GFP-LC3-expressing cells were subjected to nutrient depletion in
the presence of the lysosomal protease inhibitors (50 nM
bafilomycin A1, 5 mg/ml E64D, 5 mg/ml leupeptin and 5 mg/ml
pepstatin A). At the end of treatment, Cells were fixed with 4%
formaldehyde in PBS (pH 7.4) for 15 min. To determine the
autophagic response, cells are inspected at 606magnification for
total number of GFP-LC3 puncta. At least 150 cells are scored in
each treatment [38].
Measurement of cellular ATP
Cellular ATP was measured using a luminescence ATP
detection assay system (ATPlite kit, PerkinElmer, Boston, MA).
Autophagy and Breast Cancer
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to the manufacturer’s instruction. The luminescence was detected
on a PerkinElmer Victor 3 plate reader as counts per second
(CPS). The relative ATP level was calculated by dividing the CPS
of the treated samples by that of control samples.
Cell viability assay
Cell viability was determined using MTT assay. Briefly, cells
were seeded in 96-well tissue culture plates and subjected to
different treatments. At the end of treatments, cells were incubated
with 20 ml of 5 mg/ml MTT reagent. After 4-hour incubation at
37uC in a humidified atmosphere containing 5% CO2, formazan
crystals were dissolved in 200 ml of DMSO. Absorbance at
570 nm was determined using a PerkinElmer Victor3 plate reader.
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